Galectin Therapeutics Inc. (GALT) Trading Up 7.3%
Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) were up 7.3% on Monday . The company traded as high as $2.25 and last traded at $2.20, with a volume of 206,461 shares trading hands. The stock had previously closed at $2.05.
Several analysts have commented on GALT shares. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Galectin Therapeutics in a report on Thursday. FBR & Co restated a “buy” rating on shares of Galectin Therapeutics in a report on Thursday, May 19th. Finally, Roth Capital started coverage on shares of Galectin Therapeutics in a report on Friday, July 1st. They set a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Galectin Therapeutics presently has an average rating of “Buy” and an average price target of $8.58.
The company has a 50 day moving average of $1.58 and a 200 day moving average of $1.44. The company’s market cap is $63.75 million.
Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. Analysts anticipate that Galectin Therapeutics Inc. will post ($0.97) earnings per share for the current fiscal year.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.